Molecular monitoring of tumor-derived alterations has an established role in the surveillance of leukemias, and emerging nucleic acid sequencing technologies are likely to similarly transform the clinical management of lymphomas. Lymphomas are well suited for molecular surveillance due to relatively high cell-free DNA and circulating tumor DNA concentrations, high somatic mutational burden, and the existence of stereotyped variants enabling focused interrogation of recurrently altered regions. Here, we review the clinical scenarios and key technologies applicable for the molecular monitoring of lymphomas, summarizing current evidence in the literature regarding molecular subtyping and classification, evaluation of treatment response, the surveillance of active cellular therapies, and emerging clinical trial strategies.

中文翻译：

---

淋巴瘤的分子监测


肿瘤源性改变的分子监测在白血病监测中发挥着既定作用，新兴的核酸测序技术可能会类似地改变淋巴瘤的临床管理。由于相对较高的无细胞 DNA 和循环肿瘤 DNA 浓度、较高的体细胞突变负荷以及能够对反复改变的区域进行集中询问的定型变异的存在，淋巴瘤非常适合分子监测。在这里，我们回顾了适用于淋巴瘤分子监测的临床情况和关键技术，总结了文献中有关分子亚型和分类、治疗反应评估、活性细胞疗法监测和新兴临床试验策略的当前证据。